Facebook advance care planning tool wins design competition

Laura Pedulli | | Health Exec | Precision Medicine

An advance care planning tool that incorporates Facebook won California HealthCare Foundation’s (CHCF’s) design completion, "Catalyzing Communication About End-of-Life Care.”

The foundation launched the challenge to uncover new approaches to encourage people to complete advance care plans and to communicate their end-of-life wishes to loved ones. The winning entry, "Advance Care Planning on Facebook: Reaching the Non-Activated," identified Facebook as a platform for sharing care planning decisions with family and friends while prompting them to do the same.

CHCF is funding TrueNorth Healthcare to develop a platform that makes it easy to choose a healthcare advocate, and also encourage others to do the same by invitations through Facebook.

See the winning design here.

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.